- Home
- SRAD vs BPMC Comparison
SRAD vs BPMC Comparison
Compare SRAD & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRAD
- BPMC
- Stock Information
- Founded
- SRAD 2001
- BPMC 2008
- Country
- SRAD Switzerland
- BPMC United States
- Employees
- SRAD N/A
- BPMC N/A
- Industry
- SRAD Computer Software: Programming Data Processing
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- SRAD Technology
- BPMC Health Care
- Exchange
- SRAD Nasdaq
- BPMC Nasdaq
- Market Cap
- SRAD 5.2B
- BPMC 5.8B
- IPO Year
- SRAD 2021
- BPMC 2015
- Fundamental
- Price
- SRAD $21.62
- BPMC $88.51
- Analyst Decision
- SRAD Strong Buy
- BPMC Buy
- Analyst Count
- SRAD 12
- BPMC 22
- Target Price
- SRAD $23.17
- BPMC $124.29
- AVG Volume (30 Days)
- SRAD 1.2M
- BPMC 958.8K
- Earning Date
- SRAD 03-19-2025
- BPMC 05-01-2025
- Dividend Yield
- SRAD N/A
- BPMC N/A
- EPS Growth
- SRAD N/A
- BPMC N/A
- EPS
- SRAD 0.11
- BPMC N/A
- Revenue
- SRAD $1,145,621,700.00
- BPMC $508,824,000.00
- Revenue This Year
- SRAD $15.40
- BPMC $45.43
- Revenue Next Year
- SRAD $12.14
- BPMC $32.80
- P/E Ratio
- SRAD $193.02
- BPMC N/A
- Revenue Growth
- SRAD 26.09
- BPMC 104.04
- 52 Week Low
- SRAD $9.17
- BPMC $80.68
- 52 Week High
- SRAD $23.49
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- SRAD 51.08
- BPMC 43.04
- Support Level
- SRAD $21.11
- BPMC $86.99
- Resistance Level
- SRAD $22.66
- BPMC $93.04
- Average True Range (ATR)
- SRAD 1.15
- BPMC 3.36
- MACD
- SRAD 0.07
- BPMC 0.32
- Stochastic Oscillator
- SRAD 54.72
- BPMC 29.62
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.